Pfizer Inc. PFE
Nov 4, 2026, 9:31 AM EST
- YTD
- +23.37%
- 1 year
- +26.42%
- Market cap
- 175.10B
- Revenue (ttm)
- 63.70B
- Profit margin
- 6.80%
- EPS (ttm)
- 0.70
- Shares out
- 5.70B
- P/E ratio
- 43.89
- Forward P/E
- 10.36
- Dividend
- 1.72 (5.84%)
- Ex-dividend date
- Nov 5, 2026
- YTD return
- +23.37%
- 1-year return
- +26.42%
- Volume
- 712.92K
- Avg volume
- 33.77M
- Open
- 30.68
- Previous close
- 30.00
- Day's range
- 30.65 – 30.82
- 52-week range
- 23.62 – 31.06
- Beta
- 0.30
- Analysts
- Buy
- Price target
- 29.26 (-4.8%)
- Earnings date
- Feb 2, 2027
5D +0.71 (+2.36%)
Key statistics
- Enterprise value
- 226.89B
- PEG ratio
- 14.05
- Price / sales
- 2.68
- Price / book
- 2.01
- Dividend yield
- 5.61%
- Payout ratio
- 226.32%
- Revenue growth
- 2.60%
- Free cash flow
- 12.49B
- Total cash
- 11.70B
- Total debt
- 63.48B
- Return on equity
- 5.01%
- Short % of float
- 2.42%
- 50-day average
- 28.60
- 200-day average
- 26.82
Analyst view
Consensus: buy
- Target (low)
- 25.00
- Target (mean)
- 29.26
- Target (high)
- 36.00
- Strong buy1
- Buy8
- Hold17
- Sell1
- Strong sell1
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 0.70613.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 27, 2026 | 0.72 | — | — | — |
| Nov 3, 2026 | Sep 27, 2026 | 0.735 | 0.87 | +0.14 | +18.37% |
| Aug 4, 2026 | Jun 28, 2026 | 0.682 | 0.77 | +0.09 | +12.90% |
| May 5, 2026 | Mar 29, 2026 | 0.722 | 0.75 | +0.03 | +3.88% |
| Feb 3, 2026 | Dec 31, 2025 | 0.567 | 0.66 | +0.09 | +16.40% |
| Nov 4, 2025 | Sep 28, 2025 | 0.633 | 0.87 | +0.24 | +37.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 6, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | main | Hold | Hold |
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| Jul 13, 2026 | BMO Capital | main | Outperform | Outperform |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- pfizer.com
News
Pfizer: 3 Key Takeaways for Long-Term Investors
Amazon, Pfizer, Eaton And A Financial Stock On CNBC's ‘Final Trades'
Amazon, Pfizer, Eaton And A Financial Stock On CNBC’s ‘Final Trades’
Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone
Pfizer Q3 Earnings Call Highlights
Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial
Roth IRA vs. Taxable Account: How Much of $11,400 in Dividends Would You Keep?
Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings
Your note
Sign in to keep a note on PFE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLAYLOCK RONALD E | Director | Purchase | Aug 4, 2026 | 71,688 |
| BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) | Feb 24, 2026 | 162,088 |
| BOURLA ALBERT | Chief Executive Officer | Purchase | Aug 11, 2026 | 435,555 |
| BUCKLEY MORTIMER J. | Director | Purchase | Aug 4, 2026 | 37,632 |
| DAMICO JENNIFER B. | Officer | Sale | Aug 4, 2026 | 28,611 |
| FONSECA LIDIA PH.D. | Officer | Conversion of Exercise of derivative security | Feb 24, 2026 | 46,455 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.29% | 529,670,433 | 15.88B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 372,149,852 | 11.16B | Jun 29, 2026 |
| State Street Corporation | 5.39% | 307,090,897 | 9.21B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.37% | 135,275,782 | 4.06B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.09% | 119,235,030 | 3.57B | Jun 29, 2026 |
| Fisher Asset Management, LLC | 1.91% | 109,067,291 | 3.27B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 180,944,898 | 5.42B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 147,700,066 | 4.43B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 75,946,889 | 2.28B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 73,983,903 | 2.22B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 70,581,611 | 2.12B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.95% | 54,248,096 | 1.63B | Jun 29, 2026 |
